In the present trial, 44 patients with episodic migraine were enrolled and underwent 2- months nanocurcumin or placebo supplementation to evaluate the effects of nano-curcumin on resistin, visfatin, and MCP-1 levels and clinical manifestation of headache in migraine patients. This evidence concerns the gene CCL2 and Headache.